Results 111 to 120 of about 8,460 (122)

Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone

Expert Opinion on Drug Safety, 2023
Renáta Bor, Anna Fábián, Anita Bálint   +2 more
exaly  

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis

Therapeutic Advances in Gastroenterology, 2023
Andrea Buda, Brigida Barberio, Edoardo Savarino   +2 more
exaly  

A safety evaluation of budesonide MMX for the treatment of ulcerative colitis

Expert Opinion on Drug Safety, 2018
Simone Saibeni, Claudio Papi, Stefano Festa   +2 more
exaly  

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study

Gastroenterology, 2012
Simon Travis, Luigi Moro, E David Ballard   +2 more
exaly  

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis

United European Gastroenterology Journal, 2019
Gionata Fiorino, Stefanos Bonovas, Silvio Danese   +2 more
exaly  

Expert Review of Gastroenterology & Hepatology

Expert Review of Gastroenterology and Hepatology, 2019
Paolo Gionchetti, Fernando Rizzello, Marco Salice   +2 more
exaly  

Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis

Drugs, 2015
Sheridan M Hoy
exaly  

Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX

Scandinavian Journal of Gastroenterology, 2018
Simon Mark Dahl Jørgensen, Mette Julsgaard   +1 more
exaly  

Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.

Journal of Crohn's and Colitis, 2010
G R D'Haens, P Marteau, P Vergauwe
exaly